Table S4 shows the moleculared used in the pharmacological screen and the corresponding IC50 values

Full plasmid sequences and maps for BRAF expression constructs used in this study.

Supplementary Table 1 from Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Full reference information for studies cited in Supplementary Table 3.

Supplementary Figure 6 from Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Supplementary Figure 4 from Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Supplementary Figure 8 from Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Table S3 shows unique mutations in A375 VCR cells compared to parental using exome sequencing

Supplementary Figures 1-2 from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors

Supplementary Figures 1-8, with corresponding legends.

Sampling from the literature, highlighting methodology used for resistance modeling.

Supplementary Figure 3 from Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Supplementary Figure 5 from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors

Supplementary Figure 5 from Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Mean viability data from small molecule screen.

More exhaustive version of the materials and methods section.

Supplementary Figure 1 from Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation

Supplementary Figure 2 from Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation

Supplementary Figure 9 from Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

PDF file - 528K, G6976 inhibits EGFR mutant NSCLC cells independently of PKC inhibition.